Nektar Therapeutics
$ 65.90
-6.35%
26 Feb - close price
- Market Cap 1,968,919,000 USD
- Current Price $ 65.90
- High / Low $ 70.99 / 64.50
- Stock P/E N/A
- Book Value 4.33
- EPS -10.11
- Next Earning Report 2026-03-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -1.80 %
- 52 Week High 75.67
- 52 Week Low 6.48
About
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
Analyst Target Price
$129.86
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-08 | 2025-05-07 | 2025-03-03 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-04 | 2023-11-07 | 2023-08-08 | 2023-05-09 | 2023-02-28 |
| Reported EPS | -1.87 | -2.95 | -0.2404 | -0.15 | -0.18 | -0.25 | -0.19 | -0.22 | -0.24 | -0.27 | -0.32 | -0.32 |
| Estimated EPS | -0.1928 | -0.2 | -0.19 | -0.195 | -0.21 | -0.2 | -0.19 | -0.21 | -0.2 | -0.28 | -0.25 | -0.45 |
| Surprise | -1.6772 | -2.75 | -0.0504 | 0.045 | 0.03 | -0.05 | 0 | -0.01 | -0.04 | 0.01 | -0.07 | 0.13 |
| Surprise Percentage | -869.917% | -1375% | -26.5263% | 23.0769% | 14.2857% | -25% | 0% | -4.7619% | -20% | 3.5714% | -28% | 28.8889% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-11 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -2.69 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NKTR
2026-02-26 23:52:11
Nektar Therapeutics will announce its financial results for the fourth quarter and year-ended December 31, 2025, on Thursday, March 12, 2026, after the close of U.S.-based financial markets. President and CEO Howard Robin will host a conference call at 5:00 p.m. Eastern Time to discuss the results, which will be accessible via webcast on the company's investor relations website. The company is a clinical-stage biotechnology firm focusing on treatments for autoimmune and chronic inflammatory diseases, with several product candidates in various clinical trial phases.
2026-02-26 22:52:12
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025, on Thursday, March 12, 2026, after the close of U.S.-based financial markets. President and CEO Howard Robin will host a conference call at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results, with a live audio-only webcast available on the company’s Investors page. Recent company history includes multiple capital raises and positive Phase 2b data releases for its lead product candidate, rezpegaldesleukin.
2026-02-25 21:04:00
Nektar Therapeutics (NKTR) has seen its average one-year price target increased by 13.48% to $132.45 per share, up from $116.72. This new target represents a 93.59% increase from the last reported closing price of $68.42. Institutional ownership of NKTR has also grown, with 231 funds reporting positions and a 19.21% increase in total shares owned by institutions over the last three months.
2026-02-25 00:52:12
Nektar Therapeutics (Nasdaq: NKTR) announced its participation in two investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference in Boston and the 2026 Jefferies Biotech on the Beach Summit in Miami. Management will give a webcast presentation at the TD Cowen conference and will be available for one-on-one meetings at the Jefferies Summit. The company is a clinical-stage biotechnology firm focused on treatments for autoimmune and chronic inflammatory diseases.
2026-02-24 23:53:04
Nektar Therapeutics (Nasdaq: NKTR) announced its management will participate in two investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference in Boston and the Jefferies Biotech on the Beach Summit in Miami. The TD Cowen presentation will be webcast on March 4, 2026, and one-on-one meetings at Jefferies will be available by request. This announcement follows recent positive clinical data and equity offerings for the company.
2026-02-24 18:00:00
Nektar Therapeutics announced its participation in two investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference in Boston and the Jefferies Biotech on the Beach Summit in Miami. Management will present at the TD Cowen conference, with a webcast available, and will be available for one-on-one meetings at the Jefferies summit. The company, a clinical-stage biotechnology firm, focuses on developing treatments for autoimmune and chronic inflammatory diseases.
